Intas Pharmaceuticals Limited — Fludarabine Exporter Profile
Indian Pharmaceutical Exporter · #1 for Fludarabine · $1.9M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #1 Indian exporter of Fludarabine with $1.9M in export value and 167 verified shipments. Intas Pharmaceuticals Limited holds a 64.3% market share in Fludarabine exports across 9 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Fludarabine Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Fludarabine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $445.1K | 35 | 26.5% |
| POLAND | $435.9K | 19 | 26.0% |
| FRANCE | $256.7K | 10 | 15.3% |
| UNITED KINGDOM | $178.6K | 5 | 10.7% |
| ITALY | $126.9K | 5 | 7.6% |
| CANADA | $100.0K | 2 | 6.0% |
| SPAIN | $64.5K | 3 | 3.8% |
| HUNGARY | $59.4K | 88 | 3.5% |
| SWITZERLAND | $9.4K | 1 | 0.6% |
Intas Pharmaceuticals Limited exports Fludarabine to 9 countries. The largest destination is NETHERLANDS accounting for 26.5% of Intas Pharmaceuticals Limited's Fludarabine shipments, followed by POLAND (26.0%) and FRANCE (15.3%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fludarabine from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | HUNGARY | $287.6K | 37 |
| ACCORD HEALTHCARE POLSKA SP. Z O.O. | POLAND | $201.7K | 9 |
| BROCACEF NL : HUB | NETHERLANDS | $194.2K | 13 |
| ACCORD UK | UNITED KINGDOM | $178.6K | 5 |
| ALLOGA FRANCE | FRANCE | $152.3K | 6 |
| ACCORD HEALTHCARE POLSKA SP.Z.O.O. | POLAND | $141.8K | 6 |
| ACCORD HEALTHCARE INC., | CANADA | $100.0K | 2 |
| ACCORD HEALTHCARE ITALIA SRL | ITALY | $73.6K | 3 |
| BROCACEF NL HUB | NETHERLANDS | $71.3K | 7 |
| ACCORD HEALTHCARE POLSKA SP Z O O | POLAND | $70.8K | 3 |
Intas Pharmaceuticals Limited supplies Fludarabine to 19 buyers globally. The largest buyer is TO THE ORDER (HUNGARY), followed by ACCORD HEALTHCARE POLSKA SP. Z O.O. (POLAND) and BROCACEF NL : HUB (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fludarabine Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $2.4M worth of Fludarabine through 387 shipments from 64 suppliers to 49 countries, serving 130 buyers globally. Intas Pharmaceuticals Limited contributes $1.9M to this total, accounting for 64.3% of India's Fludarabine exports. Intas Pharmaceuticals Limited ships Fludarabine to 9 countries through 19 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Fludarabine Exports?
Intas Pharmaceuticals Limited's average Fludarabine shipment value is $11.1K per consignment, based on 167 shipments totaling $1.9M. The largest destination is NETHERLANDS (26.5% of Intas Pharmaceuticals Limited's Fludarabine exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Fludarabine Exporters?
Intas Pharmaceuticals Limited ranks #1 among 64 Indian Fludarabine exporters with a 64.3% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($1.9M), AXA PARENTERALS LIMITED ($250.0K), UNITED BIOTECH PRIVATE LIMITED ($114.2K). Intas Pharmaceuticals Limited processed 167 shipments to 9 destination countries.
What Fludarabine Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI FLUDARABINEPHOINJ25M | $137.5K | 7 |
| PHARMA DRUGS & MEDI FLUDARABINE PHO INJ | $118.4K | 3 |
| PHR DRUSG&MEDI FLUDARABINEPHOINJ25MG/ML2MLX1V(ACO- POLAN DETAILS AS PER INVOICE | $103.7K | 3 |
| PHARMA DRUGS & MEDI: FLUDARABINEPHOINJ25 | $101.1K | 20 |
| PH.DRU.& MED.: FLUDARABINE PHOSHATE INJE | $100.0K | 2 |
| PHARM DRUG&MED FLUDARABINEPHOINJ25MG/ML2MLX1V(ACO? FRANC)EACH ML CONT FLUDARABINE PHOSPHATE PH.EUR 25MG WATER(ASPERINV) | $53.9K | 2 |
| PHR DRUSG MEDI FLUDARABINEPHOINJ25MG ML2MLX1V ACO POLAN DETAILS AS PER INVOICE | $53.6K | 2 |
| PHARMACEUTICAL DRUGS AND MEDICINE FLUDARABINEPHOINJ25MG ML2MLX1V ACO AS PER INVOICE | $53.3K | 2 |
| PHARMA DRUGS & MEDI FLUDARABINEPHOSINJ25 | $50.9K | 4 |
| PHARMA DRUGS & MEDI: FLUDARABINEPHOINJ25MG/ML2MLX1V (ACO-POLAN 2705X1X1VIAL AS PER INVOICE | $50.0K | 1 |
Intas Pharmaceuticals Limited exports 97 distinct Fludarabine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI FLUDARABINEPHOINJ25M with 7 shipments worth $137.5K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Intas Pharmaceuticals Limited Compare to Nearest Fludarabine Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED ★ | $1.9M | 167 | 9 | $11.1K |
| 2 | AXA PARENTERALS LIMITED | $250.0K | 5 | 1 | $50.0K |
| 3 | UNITED BIOTECH PRIVATE LIMITED | $114.2K | 25 | 8 | $4.6K |
Intas Pharmaceuticals Limited ranks #1 among 64 Indian Fludarabine exporters. Average shipment value of $11.1K compared to the market average of $37.9K. The closest competitors by value are AXA PARENTERALS LIMITED and UNITED BIOTECH PRIVATE LIMITED.
Which Indian Ports Ship Fludarabine Exports?
| Port | Shipments | % Share |
|---|---|---|
| AHEMDABAD AIR ACC (INAMD4) | 79 | 20.4% |
| SAHAR AIR | 68 | 17.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 54 | 14.0% |
| DELHI AIR | 31 | 8.0% |
| AHEMDABAD AIR | 24 | 6.2% |
| MUNDRA SEA (INMUN1) | 21 | 5.4% |
| Mundra | 21 | 5.4% |
| DELHI AIR CARGO ACC (INDEL4) | 19 | 4.9% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Fludarabine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Fludarabine, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fludarabine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fludarabine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 168 individual customs records matching Intas Pharmaceuticals Limited exporting Fludarabine, covering 97 formulations to 9 countries via 19 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 49+ countries, 130+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fludarabine Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Fludarabine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Fludarabine Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fludarabine. For current shipment-level data, contact TransData Nexus.